This fund is no longer traded. It was delisted on August 27, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Luminex Corp. is a biotechnology company that develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. The company's core technology platform, xMAP, enables simultaneous analysis of multiple bioassays from minimal sample volumes, utilizing microscopic polystyrene beads and advanced optical systems. Luminex offers a comprehensive portfolio including the Luminex 100/200 and FLEXMAP 3D systems for laboratory analysis, the MAGPIX multiplexing analyzer for protein and nucleic acid quantification, and the ARIES real-time PCR platform for infectious disease detection. The company provides xTAG assays for respiratory and gastrointestinal pathogen identification, along with IVD kits for cystic fibrosis genotyping and pharmacogenetic profiling. Additionally, Luminex supplies flow cytometry instruments such as Amnis imaging flow cytometers and Guava benchtop analyzers, complemented by specialized software solutions like xPONENT and SYNCT for workflow optimization. Founded in 1995 and headquartered in Austin, Texas, Luminex serves clinical diagnostic laboratories, pharmaceutical researchers, and biomedical research institutions globally, with operations across North America, Europe, and Asia.
The latest articles about LMNX.
Summary of Apr 12's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about LMNX also mention these. Each card shows that asset’s own numbers for the past 24 hours.